Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of HRS-1596 in Healthy and Obese Participants
NCT07841860Phase 1Not yet recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and type 2 diabetes mellitus (T2DM) comparing HRS-1596 Group with HRS-1596 Placebo Group (2 arms). Primary endpoint: Adverse Events. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
HRS-1596
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07841860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07841860.